Loading…
Erasca, Inc. is projected to rise to $14.90 by 2027, a +19% move from its current price of $12.47. ERAS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $11.90 | $12.48 | $13.08 | +0.06% |
| May 30 | $11.68 | $12.49 | $13.35 | +0.13% |
| May 31 | $11.51 | $12.49 | $13.56 | +0.19% |
| Jun 1 | $11.37 | $12.50 | $13.74 | +0.26% |
| Jun 2 | $11.25 | $12.51 | $13.91 | +0.32% |
| Jun 3 | $11.15 | $12.52 | $14.06 | +0.38% |
| Jun 4 | $11.05 | $12.53 | $14.20 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.05 | $12.53 | $14.20 | +0.45% |
| Week 2 | $10.54 | $12.58 | $15.02 | +0.90% |
| Week 3 | $10.17 | $12.64 | $15.70 | +1.35% |
| Week 4 | $9.88 | $12.69 | $16.31 | +1.80% |
| Week 5 | $9.64 | $12.75 | $16.87 | +2.25% |
| Week 6 | $9.42 | $12.81 | $17.41 | +2.71% |
| Week 7 | $9.24 | $12.87 | $17.92 | +3.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Its product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
The company has license agreements with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds.
The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015.
Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
ERAS is a healthcare stock trading at $12.47 with a market cap of $3.88B.
It is ranked 1528 by market capitalization, placing it among smaller-cap peers within the broader market segment.
The price outlook is upside-oriented, with a year-by-year forecast showing growth from a current level of $12.47 in 2026 toward substantially higher levels by 2050. The forecast spans a wide range, with 2026 min $3.49, avg $12.47, max $19.47 and 2050 max $531.85. Long-run averages rise from $12.47 in 2026 to $32.00 in 2030, $86.67 in 2040, and $231.24 in 2050, accompanied by progressively larger max values (e.g., 2030 max $53.67, 2040 max $180.47, 2050 max $531.85).
ROI figures accompany the yearly averages, including 19.4 in 2027, 156.6 in 2030, 595 in 2040, and 1754.4 in 2050.
A major floor 89.4% below — a decisive break under it would weaken the trend.
The nearest floor, 26.9% below — buyers have tended to step in here.
The nearest ceiling, 80.2% above — a clean break opens room to run.
A major ceiling 124.9% above — clearing it would confirm fresh momentum.
Key ERAS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ERAS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.59 | Buy | $11.62 | Buy |
| MA 10 | $10.96 | Buy | $11.33 | Buy |
| MA 20 | $10.59 | Buy | $11.86 | Buy |
| MA 50 | $14.46 | Sell | $12.97 | Sell |
| MA 100 | $12.81 | Sell | $11.89 | Buy |
| MA 200 | $7.60 | Buy | $9.17 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.80 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 233.55 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.37 | Buy |
| ROC (12) | 23.22 | Buy |
| Bollinger %B (20,2) | 1.17 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -1.48 | Sell |
| Awesome (5,34) | -2.37 | Sell |
| Ultimate (7,14,28) | 75.07 | Sell |
| Momentum (10) | 2.09 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 12.03 | Buy |
| ADX (14) | 24.36 | Buy |
| ATR (14) | 0.64 | Info |
The 30-day technical picture is bullish.
RSI(14) is 50 and the moving averages show a path from near-term support to longer-term resistance. The SMA50 is $14.46 and the SMA200 is $7.60, highlighting near-term upside potential relative to longer-term trend lines. Key supports and resistances are $9.11 and $22.47, respectively, with a 30-day price range of $9.13 to $17.04.
The security displays high historical volatility, with annualized volatility at 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.49 | $12.47 | $19.47 | 0% | Neutral | |
| $10.97 | $14.90 | $21.82 | +19% | Neutral | |
| $12.27 | $17.53 | $27.16 | +41% | Bullish | |
| $16.49 | $24.63 | $39.84 | +97% | Bullish | |
| $20.59 | $32.00 | $53.67 | +157% | Bullish | |
| $24.32 | $39.21 | $67.87 | +214% | Bullish | |
| $23.01 | $38.43 | $68.40 | +208% | Bullish | |
| $22.23 | $38.40 | $70.09 | +208% | Bullish | |
| $27.59 | $49.23 | $91.94 | +295% | Bullish | |
| $30.21 | $55.64 | $106.14 | +346% | Bullish | |
| $40.44 | $86.67 | $180.47 | +595% | Bullish | |
| $104.06 | $231.24 | $531.85 | +17.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.49 | $12.47 | $14.71 | +0.00% |
| June 2026 | $10.48 | $12.50 | $15.42 | +0.27% |
| July 2026 | $10.91 | $13.22 | $16.67 | +5.70% |
| August 2026 | $10.81 | $13.25 | $17.00 | +0.25% |
| September 2026 | $10.60 | $13.12 | $17.08 | -0.97% |
| October 2026 | $11.20 | $13.98 | $18.43 | +6.56% |
| November 2026 | $11.72 | $14.75 | $19.65 | +5.48% |
| December 2026 | $11.40 | $14.46 | $19.47 | -1.94% |
Click any year to see its month-by-month ERAS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ERAS could reach as high as $19.47, with a base case around $12.47 and support toward $3.49 — roughly 0% from $12.47. Price action looks broadly range-bound.
Expect ERAS to range from $10.97 to $21.82 through 2027. The $14.90 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
The ERAS price prediction for 2028 points to an average of $17.53 (low $12.27, high $27.16) — a potential gain of +41% on today's $12.47. Momentum favours further upside here.
In 2029, ERAS is projected to trade between $16.49 and $39.84, averaging $24.63 — a potential gain of +97% from today's $12.47. That is up +40% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Erasca, Inc.'s 2030 outlook centres on $32.00, within a $20.59 to $53.67 range. That is up +30% on the projected 2029 average. That marks a +157% change versus current levels. Momentum favours further upside here.
By 2031, ERAS could reach as high as $67.87, with a base case around $39.21 and support toward $24.32 — roughly +214% from $12.47. Buyers look set to stay in control over this stretch.
Expect ERAS to range from $23.01 to $68.40 through 2032. The $38.43 average target implies a +208% move from current prices. That is -2% versus the projected 2031 average. Momentum favours further upside here.
The ERAS price prediction for 2033 points to an average of $38.40 (low $22.23, high $70.09) — a potential gain of +208% on today's $12.47. Buyers look set to stay in control over this stretch.
In 2034, ERAS is projected to trade between $27.59 and $91.94, averaging $49.23 — a potential gain of +295% from today's $12.47. That is up +28% on the projected 2033 average. Momentum favours further upside here.
Erasca, Inc.'s 2035 outlook centres on $55.64, within a $30.21 to $106.14 range. That is up +13% on the projected 2034 average. That marks a +346% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ERAS could reach as high as $180.47, with a base case around $86.67 and support toward $40.44 — roughly +595% from $12.47. Momentum favours further upside here.
Expect ERAS to range from $104.06 to $531.85 through 2050. The $231.24 average target implies a +17.5x move from current prices. That is up +167% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ERAS today (≈ 80.192462 ERAS) could be worth
$18,543.71
+$17,543.71 (+1754%) by 2050 · US Dollar
Based on the average projected ERAS price of $231.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ERASwould be worth at today's price.
$1,000 invested in ERAS on May 27, 2025 (≈ 925.925889 ERAS) would be worth
$11,546.3
+$10,546.3 (+1054.6%) today · 11.55× · US Dollar
Based on a ERAS entry price of $1.08 vs. today's $12.47.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.12 | $1,121.4 | +12.1% |
| 1 month ago | $19.15 | $651.17 | -34.9% |
| 3 months ago | $13.57 | $918.94 | -8.1% |
| 6 months ago | $3.17 | $3,933.75 | +293.4% |
| 1 year ago | $1.08 | $11,546.3 | +1054.6% |
| All time (4.9y) ago | $17.43 | $715.43 | -28.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ERAS forecast.
Our base-case forecast reaches $25.00 around 2030.
Implied market cap at $25.00: $7.77B
The multi-year forecast indicates a bullish trajectory, with meaningful upside over the coming years. By 2030, the average price is projected at $32.00 and the ROI is 156.6. The forecast also shows substantial upside by 2040 (avg $86.67; ROI 595) and by 2050 (avg $231.24; ROI 1754.4).
These are estimates and not guarantees; the numbers reflect modeled projections and carry inherent uncertainty. Investors should consider the wide potential range and the fact that sentiment evolves over time, even as the forecast remains bullish in later years.
Tap a question to reveal the answer.
The forecast lists an avg price of $32.00, a min of $20.59, a max of $53.67, and a ROI of 156.6%, with sentiment BULLISH.
The long-run projections show rising averages and positive ROIs across several years (e.g., 2027 ROI 19.4, 2028 ROI 40.6, 2029 ROI 97.5, 2030 ROI 156.6, 2040 ROI 595, 2050 ROI 1754.4). These are estimates, not guarantees, and should be weighed against risk.
Yes. By 2050 the avg price is $231.24 and the max is $531.85, indicating potential to surpass $100, with 2040 avg $86.67 and 2030 avg $32.00.
Current price is $12.47 and market cap is $3.88B.
Sentiment is BULLISH. RSI(14) is 50; SMA50 is $14.46; SMA200 is $7.60. Support is $9.11 and resistance is $22.47, with a 30-day range of $9.13 to $17.04 and annualized volatility of 90%.
Erasca, Inc. Community Discussion
0Share your Erasca, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.